Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Jonathan Brotchie

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Living Beings

Anatomy

Activities & Behaviors

Concepts & Ideas

Drug Dose-Response Relationship

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
50
Crossman, Alan
17
Fox, Susan
15
Hill, Michael
15
Bezard, Erwan
13
Henry, Brian
11
Maneuf, YP
10
Ravenscroft, Paula
10
Johnston, Tom
8
Visanji, Naomi
7
Fox, Susan
6
Gross, Christian
6
McGuire, Steven
6
Mitchell, Ian
6
Nash, Joanne
5
Silverdale, Monty

Sign-in to see all Coauthors

Publications

TOP 3
Visanji Naomi P; Fox Susan H; Johnston Tom; Reyes Gabriela; Millan Mark J; Brotchie Jonathan M
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Koprich James B; Johnston Tom H; Huot Philippe; Fox Susan H; Brotchie Jonathan M
New insights into the organization of the basal ganglia.
Fox Susan H; Chuang Rosalind; Brotchie Jonathan M
Serotonin and Parkinson's disease: On movement, mood, and madness.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jonathan Brotchie (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Visanji Naomi P; Fox Susan H; Johnston Tom; Reyes Gabriela; Millan Mark J; Brotchie Jonathan M
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Neurobiology of disease 2009;35(2):184-92.
2009: Koprich James B; Johnston Tom H; Huot Philippe; Fox Susan H; Brotchie Jonathan M
New insights into the organization of the basal ganglia.
Current neurology and neuroscience reports 2009;9(4):298-304.
2009: Fox Susan H; Chuang Rosalind; Brotchie Jonathan M
Serotonin and Parkinson's disease: On movement, mood, and madness.
Movement disorders : official journal of the Movement Disorder Society 2009;24(9):1255-66.
2009: Brotchie Jonathan; Fitzer-Attas Cheryl
Mechanisms compensating for dopamine loss in early Parkinson disease.
Neurology 2009;72(7 Suppl):S32-8.
2009: Visanji N P; Fox S H; Johnston T H; Millan M J; Brotchie J M
Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques.
The Journal of pharmacology and experimental therapeutics 2009;328(1):276-83.
2008: Fox Susan H; Brotchie Jonathan M; Lang Anthony E
Non-dopaminergic treatments in development for Parkinson's disease.
Lancet neurology 2008;7(10):927-38.
2008: Visanji Naomi P; de Bie Rob M A; Johnston Tom H; McCreary Andrew C; Brotchie Jonathan M; Fox Susan H
The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2008;23(13):1922-5.
2008: Lopez Sebastien; Turle-Lorenzo Nathalie; Johnston Tom H; Brotchie Jonathan M; Schann Stephan; Neuville Pascal; Amalric Marianne
Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.
Neuropharmacology 2008;55(4):483-90.
2008: Robb Ellen L; Winkelmolen Lieke; Visanji Naomi; Brotchie Jonathan; Stuart Jeffrey A
Dietary resveratrol administration increases MnSOD expression and activity in mouse brain.
Biochemical and biophysical research communications 2008;372(1):254-9.
2008: Nicholas Anthony P; Lubin Farah D; Hallett Penelope J; Vattem Padmapriya; Ravenscroft Paula; Bezard Erwan; Zhou Shaobo; Fox Susan H; Brotchie Jonathan M; Sweatt J David; Standaert David G
Striatal histone modifications in models of levodopa-induced dyskinesia.
Journal of neurochemistry 2008;106(1):486-94.
2008: Visanji Naomi P; Orsi Antonia; Johnston Tom H; Howson Patrick A; Dixon Kimberly; Callizot Noelle; Brotchie Jonathan M; Rees Daryl D
PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2008;22(7):2488-97.
2008: Jugloff Denis G M; Vandamme Katrina; Logan Richard; Visanji Naomi P; Brotchie Jonathan M; Eubanks James H
Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice.
Human molecular genetics 2008;17(10):1386-96.
2008: Lee Joohyung; Gomez-Ramirez Jordi; Johnston Tom H; Visanji Naomi; Brotchie Jonathan M
Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.
Synapse (New York, N.Y.) 2008;62(4):310-3.
2008: Fox Susan H; Chuang Rosalind; Brotchie Jonathan M
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Progress in brain research 2008;172():479-94.
2007: Shin D S; Samoilova M; Cotic M; Zhang L; Brotchie J M; Carlen P L
High frequency stimulation or elevated K+ depresses neuronal activity in the rat entopeduncular nucleus.
Neuroscience 2007;149(1):68-86.
2007: Fabbrini Giovanni; Brotchie Jonathan M; Grandas Francisco; Nomoto Masahiro; Goetz Christopher G
Levodopa-induced dyskinesias.
Movement disorders : official journal of the Movement Disorder Society 2007;22(10):1379-89; quiz 1523.
2007: Hallett Penelope J; Brotchie J M
Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia.
Movement disorders : official journal of the Movement Disorder Society 2007;22(1):28-40.
2006: Hill Michael P; Ravenscroft Paula; McGuire Steven G; Brotchie Jonathan M; Crossman Alan R; Rochat Catherine; Millan Mark J
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
Movement disorders : official journal of the Movement Disorder Society 2006;21(12):2090-5.
2006: Visanji Naomi P; Gomez-Ramirez Jordi; Johnston Tom H; Pires Donna; Voon Valerie; Brotchie Jonathan M; Fox Susan H
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2006;21(11):1879-91.
2006: Visanji Naomi P; Millan Mark J; Brotchie Jonathan M
Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
Experimental neurology 2006;202(1):85-92.
2006: Schapira Anthony H V; Bezard Erwan; Brotchie Jonathan; Calon Frédéric; Collingridge Graham L; Ferger Borris; Hengerer Bastian; Hirsch Etienne; Jenner Peter; Le Novère Nicolas; Obeso José A; Schwarzschild Michael A; Spampinato Umberto; Davidai Giora
Novel pharmacological targets for the treatment of Parkinson's disease.
Nature reviews. Drug discovery 2006;5(10):845-54.
2006: Fox Susan H; Lang Anthony E; Brotchie Jonathan M
Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.
Movement disorders : official journal of the Movement Disorder Society 2006;21(10):1578-94.
2006: Fox Susan H; Visanji Naomi P; Johnston Tom H; Gomez-Ramirez Jordi; Voon Valerie; Brotchie Jonathan M
Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.
Archives of neurology 2006;63(9):1343-4.
2006: Lee Joohyung; Di Marzo Vincenzo; Brotchie Jonathan M
A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats.
Neuropharmacology 2006;51(3):557-65.
2006: Nadjar Agnes; Brotchie Jonathan M; Guigoni Celine; Li Qin; Zhou Shao-Bo; Wang Gui-Jie; Ravenscroft Paula; Georges François; Crossman Alan R; Bezard Erwan
Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2006;26(34):8653-61.
2006: Gomez-Ramirez Jordi; Johnston Tom H; Visanji Naomi P; Fox Susan H; Brotchie Jonathan M
Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2006;21(6):839-46.
2006: Alachkar Amal; Brotchie Jonathan; Jones Owen T
alpha2-Adrenoceptor-mediated modulation of the release of GABA and noradrenaline in the rat substantia nigra pars reticulata.
Neuroscience letters 2006;395(2):138-42.
2006: Johnston Tom H; Brotchie Jonathan M
Drugs in development for Parkinson's disease: an update.
Current opinion in investigational drugs (London, England : 2000) 2006;7(1):25-32.
2005: Johnston Tom H; Fox Susan H; Brotchie Jonathan M
Advances in the delivery of treatments for Parkinson's disease.
Expert opinion on drug delivery 2005;2(6):1059-73.
2005: Brotchie Jonathan M
Nondopaminergic mechanisms in levodopa-induced dyskinesia.
Movement disorders : official journal of the Movement Disorder Society 2005;20(8):919-31.
2005: Venderova Katerina; Brown Timothy M; Brotchie Jonathan M
Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus.
Experimental neurology 2005;194(1):284-7.
2005: van der Stelt Mario; Fox Susan H; Hill Michael; Crossman Alan R; Petrosino Stefania; Di Marzo Vincenzo; Brotchie Jonathan M
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(9):1140-2.
2005: Nash J E; Johnston T H; Collingridge G L; Garner C C; Brotchie J M
Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(6):583-5.
2005: Silverdale Monty A; Nicholson S L; Crossman A R; Brotchie J M
Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2005;20(4):403-9.
2005: Hallett P J; Dunah A W; Ravenscroft P; Zhou S; Bezard E; Crossman A R; Brotchie J M; Standaert D G
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Neuropharmacology 2005;48(4):503-16.
2005: Brotchie J M; Lee J; Venderova K
Levodopa-induced dyskinesia in Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2005;112(3):359-91.
2005: Johnston Tom H; Lee Joohyung; Gomez-Ramirez Jordi; Fox Susan H; Brotchie Jonathan M
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Experimental neurology 2005;191(2):243-50.
2004: Ismayilova Naila; Crossman Alan; Verkhratsky Alexei; Brotchie Jonathan
Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats.
European journal of pharmacology 2004;497(2):187-95.
2004: Nash J E; Ravenscroft P; McGuire S; Crossman A R; Menniti F S; Brotchie J M
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
Experimental neurology 2004;188(2):471-9.
2004: Hill Michael P; Brotchie Jonathan M; Crossman Alan R; Bezard Erwan; Michel Anne; Grimée Renee; Klitgaard Henrik
Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets.
Clinical neuropharmacology 2004;27(4):171-7.
2004: Johnston Tom H; Brotchie Jonathan M
Drugs in development for Parkinson's disease.
Current opinion in investigational drugs (London, England : 2000) 2004;5(7):720-6.
2004: Silverdale M A; Nicholson S L; Ravenscroft P; Crossman A R; Millan M J; Brotchie J M
Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
Experimental neurology 2004;188(1):128-38.
2004: Hill Michael P; Ravenscroft Paula; Bezard Erwan; Crossman Alan R; Brotchie Jonathan M; Michel Anne; Grimée Renee; Klitgaard Henrik
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
The Journal of pharmacology and experimental therapeutics 2004;310(1):386-94.
2004: Millan Mark J; Di Cara Benjamin; Hill Michael; Jackson Michael; Joyce Jeffrey N; Brotchie Jonathan; McGuire Steve; Crossman Alan; Smith Lance; Jenner Peter; Gobert Alain; Peglion Jean-Louis; Brocco Mauricette
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
The Journal of pharmacology and experimental therapeutics 2004;309(3):921-35.
2004: Fox Susan; Silverdale Montague; Kellett Mark; Davies Rhys; Steiger Malcolm; Fletcher Nicholas; Crossman Alan; Brotchie Jonathan
Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2004;19(5):554-60.
2004: Bezard Erwan; Hill Michael P; Crossman Alan R; Brotchie Jonathan M; Michel Anne; Grimée Renee; Klitgaard Henrik
Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.
European journal of pharmacology 2004;485(1-3):159-64.
2004: Ravenscroft Paula; Chalon Sylvie; Brotchie Jonathan M; Crossman Alan R
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Experimental neurology 2004;185(1):36-46.
2003: Brown Timothy M; Brotchie Jonathan M; Fitzjohn Stephen M
Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2003;23(35):11073-7.
2003: Bezard Erwan; Baufreton Jerome; Owens Geraint; Crossman Alan R; Dudek Hank; Taupignon Anne; Brotchie Jonathan M
Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(15):2337-8.
2003: Hill Michael P; Bezard Erwan; McGuire Steven G; Crossman Alan R; Brotchie Jonathan M; Michel Ann; Grimée Renee; Klitgaard Henrik
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
Movement disorders : official journal of the Movement Disorder Society 2003;18(11):1301-5.
2003: Henry Brian; Duty Susan; Fox Susan H; Crossman Alan R; Brotchie Jonathan M
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.
Experimental neurology 2003;183(2):458-68.
2003: Savola Juha-Matti; Hill Michael; Engstrom Mia; Merivuori Hannele; Wurster Siegfried; McGuire Steven G; Fox Susan H; Crossman Alan R; Brotchie Jonathan M
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2003;18(8):872-83.
2003: Bezard Erwan; Gross Christian E; Brotchie Jonathan M
Presymptomatic compensation in Parkinson's disease is not dopamine-mediated.
Trends in neurosciences 2003;26(4):215-21.
2003: Brotchie Jonathan M
CB1 cannabinoid receptor signalling in Parkinson's disease.
Current opinion in pharmacology 2003;3(1):54-61.
2003: Segovia Gregorio; Mora Francisco; Crossman Alan R; Brotchie Jonathan M
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2003;18(2):138-49.
2003: Silverdale Monty A; Fox S H; Crossman A R; Brotchie J M
Potential nondopaminergic drugs for Parkinson's disease.
Advances in neurology 2003;91():273-91.
2002: Fox Susan H; Henry Brian; Hill Michael; Crossman Alan; Brotchie Jonathan
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2002;17(6):1180-7.
2002: Nicholson S L; Brotchie J M
5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2002;9 Suppl 3():1-6.
2002: Davis Sue; Brotchie Jonathan; Davies Ioan
Protection of striatal neurons by joint blockade of D1 and D2 receptor subtypes in an in vitro model of cerebral hypoxia.
Experimental neurology 2002;176(1):229-36.
2002: Brown Timothy; de Groote Carmen; Brotchie Jonathan
Recent advances in the treatment of L-DOPA-induced dyskinesia.
IDrugs : the investigational drugs journal 2002;5(5):454-68.
2002: Nash Joanne E; Brotchie Jonathan M
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
Movement disorders : official journal of the Movement Disorder Society 2002;17(3):455-66.
2002: Silverdale M A; Crossman A R; Brotchie J M
Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
Experimental neurology 2002;174(1):21-8.
2002: Fox Susan H; Kellett Mark; Moore A Peter; Crossman Alan R; Brotchie Jonathan M
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.
Movement disorders : official journal of the Movement Disorder Society 2002;17(1):145-9.
2001: Sieradzan K A; Fox S H; Hill M; Dick J P; Crossman A R; Brotchie J M
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.
Neurology 2001;57(11):2108-11.
2001: Hille C J; Fox S H; Maneuf Y P; Crossman A R; Brotchie J M
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.
Experimental neurology 2001;172(1):189-98.
2001: Henry B; Fox S H; Crossman A R; Brotchie J M
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Experimental neurology 2001;171(1):139-46.
2001: Bezard E; Dovero S; Prunier C; Ravenscroft P; Chalon S; Guilloteau D; Crossman A R; Bioulac B; Brotchie J M; Gross C E
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2001;21(17):6853-61.
2001: Bezard E; Brotchie J M; Gross C E
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
Nature reviews. Neuroscience 2001;2(8):577-88.
2001: Fox S H; Henry B; Hill M P; Peggs D; Crossman A R; Brotchie J M
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.
Movement disorders : official journal of the Movement Disorder Society 2001;16(4):642-50.
2001: Silverdale M A; McGuire S; McInnes A; Crossman A R; Brotchie J M
Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.
Experimental neurology 2001;169(2):400-6.
2001: Bezard E; Ravenscroft P; Gross C E; Crossman A R; Brotchie J M
Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys.
Neurobiology of disease 2001;8(2):343-50.
2001: Bezard E; Crossman A R; Gross C E; Brotchie J M
Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2001;15(6):1092-4.
2001: Bezard E; Boraud T; Chalon S; Brotchie J M; Guilloteau D; Gross C E
Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey.
Neuroscience 2001;103(1):117-23.
2000: Fox S H; Brotchie J M
5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2000;15(6):1064-9.
2000: Nash J E; Brotchie J M
A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2000;20(20):7782-9.
2000: Nash J E; Fox S H; Henry B; Hill M P; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie J M; Crossman A R
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
Experimental neurology 2000;165(1):136-42.
2000: Di Marzo V; Hill M P; Bisogno T; Crossman A R; Brotchie J M
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2000;14(10):1432-8.
2000: Hill M P; Hille C J; Brotchie J M
Delta-opioid receptor agonists as a therapeutic approach in Parkinson's disease.
Drug news & perspectives 2000;13(5):261-8.
2000: Fox S H; Brotchie J M
5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.
European journal of pharmacology 2000;398(1):59-64.
2000: Ravenscroft P; Brotchie J
NMDA receptors in the basal ganglia.
Journal of anatomy 2000;196 ( Pt 4)():577-85.
2000: Brotchie J M
The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease.
Annals of neurology 2000;47(4 Suppl 1):S105-12; discussion S112-4.
1999: Hill M P; Brotchie J M
The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
British journal of pharmacology 1999;128(7):1577-85.
1999: Henry B; Fox S H; Peggs D; Crossman A R; Brotchie J M
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1999;14(5):744-53.
1999: Hill M P; Brotchie J M
Control of glutamate release by calcium channels and kappa-opioid receptors in rodent and primate striatum.
British journal of pharmacology 1999;127(1):275-83.
1999: Henry B; Crossman A R; Brotchie J M
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Experimental neurology 1999;155(2):204-20.
1999: Nash J E; Hill M P; Brotchie J M
Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat.
Experimental neurology 1999;155(1):42-8.
1999: Brotchie J M; Fox S H
Quantitative assessment of dyskinesias in subhuman primates.
Movement disorders : official journal of the Movement Disorder Society 1999;14 Suppl 1():40-7.
1999: Brotchie J M
Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia.
Advances in neurology 1999;80():71-85.
1998: Brotchie J M
Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1998;13(6):871-6.
1998: Richter A; Brotchie J M; Crossman A R; Löscher W
[3H]-2-deoxyglucose uptake study in mutant dystonic hamsters: abnormalities in discrete brain regions of the motor system.
Movement disorders : official journal of the Movement Disorder Society 1998;13(4):718-25.
1998: Henry B; Crossman A R; Brotchie J M
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Experimental neurology 1998;151(2):334-42.
1998: Fox S H; Moser B; Brotchie J M
Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Experimental neurology 1998;151(1):35-49.
1998: Duty S; Henry B; Crossman A R; Brotchie J M
Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat.
Experimental neurology 1998;150(2):223-34.
1998: Hughes N R; McKnight A T; Woodruff G N; Hill M P; Crossman A R; Brotchie J M
Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.
Movement disorders : official journal of the Movement Disorder Society 1998;13(2):228-33.
1998: Henry B; Crossman A R; Brotchie J M
Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia.
Advances in neurology 1998;78():53-61.
1998: Brotchie J M; Henry B; Hille C J; Crossman A R
Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease.
Advances in neurology 1998;78():41-52.
1998: Crossman A R; Brotchie J M
Pathophysiology of dystonia.
Advances in neurology 1998;78():19-25.
1997: Maneuf Y P; Crossman A R; Brotchie J M
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
Experimental neurology 1997;148(1):265-70.
1997: Brotchie J M
Novel approaches to the symptomatic treatment of parkinsonian syndromes: alternatives and adjuncts to dopamine-replacement.
Current opinion in neurology 1997;10(4):340-5.
1997: Duty S; Brotchie J M
Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression.
Experimental neurology 1997;144(2):423-32.
1997: Maneuf Y P; Brotchie J M
Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices.
British journal of pharmacology 1997;120(8):1397-8.
1997: Glass M; Brotchie J M; Maneuf Y P
Modulation of neurotransmission by cannabinoids in the basal ganglia.
The European journal of neuroscience 1997;9(2):199-203.
1996: East S J; Parry-Jones A; Brotchie J M
Ionotropic glutamate receptors and nitric oxide synthesis in the rat striatum.
Neuroreport 1996;8(1):71-5.
1996: Fox S H; Brotchie J M
New treatments for movement disorders?
Trends in pharmacological sciences 1996;17(10):339-42.
1996: Henry B; Brotchie J M
Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Drugs & aging 1996;9(3):149-58.
1996: Maneuf Y P; Nash J E; Crossman A R; Brotchie J M
Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus.
European journal of pharmacology 1996;308(2):161-4.
1996: Maneuf Y P; Duty S; Hille C J; Crossman A R; Brotchie J M
Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease.
Experimental neurology 1996;139(1):12-6.
1996: Maneuf Y P; Crossman A R; Brotchie J M
Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2.
Synapse (New York, N.Y.) 1996;22(4):382-5.
1996: Fox S; Brotchie J
Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat.
European journal of pharmacology 1996;301(1-3):27-30.
1995: Mitchell I J; Hughes N; Carroll C B; Brotchie J M
Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset.
Behavioural pharmacology 1995;6(5-6):492-507.
1995: Hill M P; Brotchie J M
Modulation of glutamate release by a kappa-opioid receptor agonist in rodent and primate striatum.
European journal of pharmacology 1995;281(1):R1-R2.
1995: Maneuf Y P; Mitchell I J; Crossman A R; Woodruff G N; Brotchie J M
Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease.
Brain research 1995;683(1):102-8.
1995: Carroll C B; Holloway V; Brotchie J M; Mitchell I J
Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms.
Psychopharmacology 1995;119(1):55-65.
1995: East S J; Hill M P; Brotchie J M
Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes.
European journal of pharmacology 1995;277(1):117-21.
1994: Maneuf Y P; Mitchell I J; Crossman A R; Brotchie J M
On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus.
Experimental neurology 1994;125(1):65-71.
1993: Brotchie J; Crossman A; Mitchell I; Duty S; Carroll C; Cooper A; Henry B; Hughes N; Maneuf Y
Chemical signalling in the globus pallidus in parkinsonism.
Progress in brain research 1993;99():125-39.
1991: Brotchie J M; Crossman A R
D-[3H]aspartate and [14C]GABA uptake in the basal ganglia of rats following lesions in the subthalamic region suggest a role for excitatory amino acid but not GABA-mediated transmission in subthalamic nucleus efferents.
Experimental neurology 1991;113(2):171-81.
1991: Mitchell I J; Brotchie J M; Brown G D; Crossman A R
Modeling the functional organization of the basal ganglia. A parallel distributed processing approach.
Movement disorders : official journal of the Movement Disorder Society 1991;6(3):189-204.
1991: Brotchie J M; Mitchell I J; Sambrook M A; Crossman A R
Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate.
Movement disorders : official journal of the Movement Disorder Society 1991;6(2):133-8.
1987: Thornton S; Brotchie J
Reminiscence: a critical review of the empirical literature.
The British journal of clinical psychology / the British Psychological Society 1987;26 ( Pt 2)():93-111.
1985: Brotchie J; Brennan J; Wyke M A
Temporal orientation in the pre-senium and old age.
The British journal of psychiatry : the journal of mental science 1985;147():692-5.

Sign-in to see more